A pilot study of the CMV inSIGHT T-cell immunity panel to assess cytomegalovirus (CMV) cell mediated immunity (CMI) in allogeneic hematopoietic cell transplant (HCT) recipients. (PubMed, Cytotherapy) - Jun 5, 2026 - "Seventy-three percent of letermovir recipients had positive CMV CMI by D 100, indicating CMV-specific immune reconstitution despite letermovir prophylaxis. Interventional studies are needed to assess the utility of the CMV inSIGHT T-cell immunity panel in guiding treatment decisions after discontinuation of letermovir prophylaxis."
Journal • Acute Graft versus Host Disease • Bone Marrow Transplantation • Cytomegalovirus Infection • Graft versus Host Disease • Immunology • Infectious Disease • Oncology • Transplantation • CD4 • CD8
|
|
Brian Shaffer; Evangelos Ntrivalas; Genovefa A Papanicolaou; Gyuri Han; Isabelle Ulloa; Jalal Siddiqui; Miguel Angel Perales; Rich Kodama; Steve Kleiboeker; Swarn Arya; Yuxuan Li
|